PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Status:
Suspended
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in
patients with recurrent medulloblastoma and malignant glioma. Patients with
histologically-proven medulloblastoma or malignant glioma who had received prior therapy for
their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any
time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine
comprised of Component A, a synthetic long peptide (SLP) of 26 amino acid residues from human
pp65. In May 2021, enrollment on the study was temporarily suspended due to delays in vialing
the PEP-CMV study vaccine.
Phase:
Phase 1
Details
Lead Sponsor:
Gary Archer Ph.D.
Collaborators:
Annias Immunotherapeutics, Inc. Pediatric Brain Tumor Foundation